Trump will first pass through Israel, addressing parliament and meeting with hostage families Monday before heading to Egypt's Sharm El-Sheikh for the summit, where a "document ending the war in the ...

(Alliance News) - Chinese firm Ming Yang Smart Energy Group Co Ltd on Friday shared plans to build the UK's largest wind turbine manufacturing facility in Scotland. The firm said the project will ...

(Alliance News) - Voters in Frankfurt an der Oder head to the polls on Sunday in a run-off that could give the far-right Alternative for Germany party its first mayoral victory in a German city.

The deal with AstraZeneca comes after New York-based peer Pfizer Inc struck a similar pricing agreement with the Trump administration last month to offer discounted drug prices directly to consumers.

(Alliance News) - Amala Foods PLC on Friday warned of the "risk" that it could fall into insolvency should new funding not materialise in the medium-term.

(Alliance News) - The FTSE 100 fell sharply into the close on Friday as US President Donald Trump threatened China with a massive increase in tariffs amid a critical minerals dispute. The FTSE 100 ...

The dieselgate scandal first erupted in September 2015, when Wolfsburg, Germany-based carmaker Volkswagen AG was found to have cheated pollution tests by installing so-called defeat devices to reduce ...

(Alliance News) - RM PLC on Friday raised approximately GBP13.5 million in gross proceeds from a placing with "strong demand". The Abingdon, England-based supplier of technology and resources to the ...

(Alliance News) - The UK's Competition & Markets Authority has rejected a merger notice for the planned acquisition of Total System Services LLC by Fidelity National Information Services Inc, or FIS.

London-based generative AI services provider said its new product, 'Invention Validator', aims to test user perception and adoption readiness for new scientific discoveries. Shares in GenIP were up ...

The FTSE 100 index was down 10.96 points, 0.1%, at 9,498.44. The FTSE 250 was down 49.34 points, 0.2%, at 22,003.49, and the AIM All-Share was down 1.77 points, 0.2%, at 791.93.

Akero's lead drug candidate efruxifermin, or EFX, is currently undergoing phase-three study, and aims to be a "best-in-class" MASH treatment. This "will complement Novo Nordisk's leadership in GLP-1 ...